What is the criteria for yervoy discount?

The criteria for Yervoy (ipilimumab) discounts can vary depending on the patient's insurance, income level, and other factors. According to DrugPatentWatch.com [1], Yervoy is a prescription medicine used to treat patients with advanced melanoma.

To be eligible for Yervoy discounts, patients often need to meet certain conditions, such as having a certain type of insurance, being a Medicare beneficiary, or participating in patient assistance programs. These programs can be administered by the manufacturer, Bristol-Myers Squibb, or third-party organizations.

One common criterion for Yervoy discounts is having Medicare or Medicaid coverage. Patients who have Medicare Part D or Medicaid coverage may be eligible for a discount on Yervoy through the Medication Therapy Management (MTM) program or the Extra Help program [2].

Another criterion is income level. Bristol-Myers Squibb offers a patient assistance program that provides Yervoy at no cost to eligible patients with cancer, including those with melanoma. To be eligible, patients must have income at or below 200% of the Federal Poverty Guidelines [3].

Additionally, some pharmaceutical assistance programs, such as the Partnership for Prescription Assistance, may also offer Yervoy discounts to patients who cannot afford the medication or have difficulty accessing it due to cost barriers [4].

It's essential for patients to consult their healthcare provider or a patient advocacy organization to determine their eligibility for Yervoy discounts and to explore available programs. This can include programs offered by the manufacturer, non-profit organizations, or government agencies.

Sources:

[1] DrugPatentWatch.com - Yervoy (ipilimumab) [https://www.drugpatentwatch.com/drug/1400-yervoy]
[2] Medicare.gov - Medication Therapy Management (MTM) [https://www.medicare.gov/pharmacies/medication-therapy-management-mtm]
[3] Bristol-Myers Squibb - Patient Assistance Program [https://www.bms.com/our-company/patient-assistance-program.html]
[4] Partnership for Prescription Assistance - Yervoy (ipilimumab) [https://www.pparx.org/meds/yervoy]